Introduction {#s1}
============

The concept of the stem cell niche was officially used for the first time by Schofield ([@B1]) in 1978 to define local environments with specific molecular and cellular characteristics that are required for the maintenance of hematopoietic stem cells. Ten years previously, Smart ([@B2]) and Altman ([@B3]) identified tissue in the brain that was thought to be capable of self renewal, namely two specific regions with proliferative capacity one localized in the subventricular zone (SVZ) of the lateral ventricle and one in the subgranular zone (SGZ) of the dentate gyrus of the hippocampus. The assay to test *in vitro* neural stem/progenitor cell (NPC)-self-renewal and multi-potency consisted of assessing their ability to give rise to neurospheres ([@B4]). *In vivo*, in mice, their self-renewal capacity was proved using targeted ablation of dividing GFAP-positive cells and by genetic lineage tracing ([@B5], [@B6]). Similarly to the hematopoietic niche and obviously in addition to the intrinsic and specific characteristics of neural stem cells (i.e., their ability to originate neuro-glia cells), the fate of NPCs and their (lifelong) self-renewal and differentiation capacity are tightly regulated by complex interactions between intrinsic and extrinsic signals provided by surrounding cells in the niche and by distant sources ([@B7]). The microenvironment of the neurogenic niche includes multiple cell populations whose interplay, including that between stem cells themselves, is still largely unknown and under active exploration. Moreover, physical activity, stress, environmental enrichment, aging, and intrinsic factors, such as cytokines, growth factors, hormones, or neurotrophins, finely regulate the fate of neural stem cells. These features are shared with all other stem niches, such as the originally identified hematopoietic niche ([@B8]). A thorough characterization of other niche components has recently been provided in Andreotti et al. ([@B9]) and in Bacigaluppi et al. ([@B10]).

Understanding the potential of endogenous or administered NPCs as well as the cross-talk between neural stem cells and their niche components is essential for identifying what can be modulated and how for the development of therapies against neurological disorders in which neural stem cell function is altered or in which its improvement might be of help.

In this review, we would like to focus on the intrinsic and comprehensive added value of neural stem cell plasticity. NSC plasticity indeed is *per se* fundamental for development but represents an important asset in a therapeutic perspective since the neurogenic niche remains an exception in the "static" brain and represents a possible unique source of new neurons useful for substantially incurable neurological disorders and brain aging problems which are a heavy social and economic burden.

We will first frame NSCs in the stem cell context and then illustrate their plasticity in a developmental perspective, summarizing the current understanding of NSC modes of division and their mechanisms of persistence in the adult. We will compare NSCs in the two neurogenic regions of the adult mammalian mouse and human brain and discuss recent controversies on neurogenesis in the adult human brain. Last, we will discuss the current therapeutic exploitation of NSC plasticity along with the technological advancements that are being implemented, to conclude with the pros and cons, the benefits and hurdles, linked to taking advantage of these assets.

Stem Cells {#s2}
==========

Stem cells (SC) are unspecialized, immature cells with self-renewing capacity, namely the ability to produce nearly identical copies of themselves for a long period of time without differentiating and with the possibility to differentiate into various cell lineages ([@B11]).

Totipotent stem cells, such as zygote cells and the first few cells from their division, can differentiate into all possible cell types. Pluripotent stem cells can instead differentiate into cells of the three embryonic layers, i.e., mesoderm, endoderm, and ectoderm, and can give rise to tissue and organ specialized cells. Multipotent stem cells, such as adult hematopoietic or neural stem cells, can differentiate into closely related families of cells to renew tissue-specific cell populations in organs, such as liver, intestinal tract, and skin. Exceptionally, this does not occur by default for the brain. Last, unipotent stem cells can differentiate only into a single cell type, usually of a single specialized tissue or organ.

SCs can also be classified according to their source of origin. Embryonic Stem Cells (ESCs) are totipotent, derive from the inner cell mass of human blastocysts, and can potentially proliferate indefinitely, giving rise to all types of cells in the human body. Adult Stem Cells are undifferentiated, totipotent, or multipotent cells able to replenish dying cells and to regenerate damaged tissues (if possible). Induced Pluripotent Stem Cells (iPSCs), recently developed by genetic reprogramming of adult, non-pluripotent somatic cells, are comparable to human ES cells, having differentiation potential *in vitro* and a capability to generate *in vivo* teratomas. iPSCs can be generated by over-expression through retro- or lenti-viral vector transduction of four transcription factors: Oct3/4, Sox2, c-Myc, and Klf4 \[c-Myc is dispensable ([@B12])\]. These cells express human ES markers (such as OCT3/4, SOX2, and NANOG) at the same or higher level than ESCs and stain positive for markers of the three germ layers, confirming their pluripotency and differentiation potential ([@B13]). They can also be generated using small molecules that mimic the effect of transcription factors ([@B14]) or by miRNAs ([@B15]). Last, Cancer Stem Cells emerge from malignant transformation of adult stem cells or from somatic cells that acquire self-renewing potential. They have been proposed as the source of tumors and of metastases and have been isolated from various tissue types ([@B16]).

Stem cells gained value in the last 15 years for the development of cell-based therapies for many serious diseases and injuries. For, example, hematopoietic stem cell transplants became established therapeutics for leukemia and for burns and corneal disorders ([@B11]). For complex neurological diseases, unfortunately not all stem cells can be exploited. In principle, ESCs would be perfect for cell replacement therapy because they can proliferate indefinitely ([@B17]), but there is also a risk of tumor formation and immune rejection along with ethical, religious, and philosophical problems. To reduce the tumor-forming potential, human ESCs could be pre-differentiated *in vitro* in committed precursor cells or neural precursor cells (NPCs) ([@B18]), which maintain self-renewal capacity and at the same time are restricted to generate only neural cells (neurons and glia) *in vivo* upon transplant, but these still raise ethical concerns. ESCs might, in principle, be directed to differentiate into specialized neuronal subtypes ([@B19]) to further reduce the risk of tumorigenicity. But more than 200 distinct neuronal subtypes with regional specificity exist, and the applicability of transplanted differentiated cells is still far from realization.

An alternative strategy is to use neural stem/precursor cells from aborted human fetuses at the gestational age of 6--20 weeks. They can be maintained, expanded, and split without losing their self-renewing and neurogenic capacity for a long period of time *in vitro*. Their main drawback, however, is the limited availability and the unpredictability of when, where, or in what conditions the material will be obtained.

It is also possible to obtain NPCs from reprogrammed somatic cells, hiPSCs, differentiated to generate NPCs with very high neurogenic potential and virtually devoid of tumorigenicity if intracerebrally transplanted ([@B20]). Moreover, iPSC-derived NSCs, unlike adult fetal NPCs, which cannot be used as an autologous cell source, offer the possibility of autologous transplantation.

Further, NPCs could also be generated via transdifferentiation (iNPCs) of a cell type into another not following the "normal" re-programmed differentiation path, because transdifferentiated cells do not become pluripotent at any time ([@B21]--[@B26]). iNPCs, similarly to NPC-derived iPSCs, are useful for transplantation therapy, for establishing disease models, and for drug screening. In principle, they hold a low risk of tumorigenesis, maintain the capacity of self-renewal, and give rise to multiple neuronal subtypes *in vitro* and *in vivo*. Indeed, specifically for the *in vivo* applicability, murine iNPCs transplanted into healthy adult mouse brain survived for 6 months without overgrowths, achieved functional integration ([@B27]), and could differentiate into neuronal cells, although they retained a mixed neuro-glia phenotype (M2+ and GFAP+) ([@B28]). In the context of spinal cord injury, iNPCs generated by transfection with four reprogramming factors and transplanted in rat spinal cord, differentiate into all neuronal lineages ([@B29]). Direct cell conversion has also been tested *in vivo* by transplanting human fibroblasts and human astrocytes engineered to express inducible neural reprogramming genes that converted fibroblasts and astrocyte cells into neurons directly in the adult rodent brain ([@B30]).

This field is still in its infancy, and before considering the development of personalized regenerative therapies with iNPCs ([@B31]), further investigation is required to better understand the detailed mechanisms occurring in the transdifferentiation processes to improve the efficiency and the maturation into desirable cells with neurotransmitter and region-specific phenotypes.

Lastly, glial-restricted progenitor cells (GRPs) represent another therapeutic alternative. They are self-renewing cells derived from CNS tissue of 19--22 gestational weeks that have a limited differentiation potential and are able to give rise to oligodendrocytes and astrocytes but not neurons, as assessed in the demyelinated shiver mouse model ([@B32]) and in transverse myelitis, an inflammatory condition of the spinal cord that leads to demyelination ([@B33]). GRPs have also been proposed for multiple sclerosis (MS) because endogenous OPCs in the lesions initially engage in remyelination ([@B34]), but with time, the number of OPCs declines and remyelination becomes inefficient ([@B35]). Isolation and expansion of GRPs were recently implemented by Q Company ([@B36]), which started a phase I clinical trial ([@B37]).

Neural Stem Cells in the Mammalian Brain: Fetal vs. Adult Compartment, Mouse vs. Human {#s3}
======================================================================================

A detailed characterization of the neural niches for both mouse and human is now available ([@B38]). In the mouse, the central nervous system (CNS) originates at E7.5--E8 with the neural plate that folds into the neural tube and then divides along the rostro-caudal axis into the rostral forebrain, midbrain, and hindbrain vesicles, while the caudal vesicle gives rise to the spinal cord. The cortical layer, adjacent to the lateral ventricles (LV) and known as the ventricular zone (VZ) is made of highly proliferating progenitors with apical basal polarity (neuroepithelial cells, NECs) ([@B38]) that, before neurogenesis (E10.5--E12.5), undergo extensive symmetric divisions to expand ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). When neurogenesis starts (E12.5 onwards), NECs become radial glial cells (RGCs), express glial markers, assume an elongated morphology, and divide asymmetrically, originating one RGC and one neuron or one RGC and one intermediate progenitor (IP, Tbr2+) ([@B43]). IPs themselves migrate radially to give rise to two pyramidal neurons that establish connection and form synapses ([@B44]). The CNS builds up in \~1 week during gestation, and NPCs (RGC/IPs) are retained in the two distinct and small proliferative areas of the SVZ and the SGZ ([@B44], [@B45]). During neurogenesis, first-born neurons populate the deeper cortical layers (V--VI), while later-born neurons progressively populate the more superficial layers (II--IV). These layers contain neuronal subtypes that are different in morphology, electrophysiological activity, axonal connectivity, and gene expression. During embryonic and late neurogenesis, RGCs, because of their elongated radial morphology, sense extrinsic cues from meninges, vasculature, newborn neurons, and cerebrospinal fluid, which regulate their cell fate decision. During late embryonic development and the first weeks after birth, radial glia also differentiate into astrocytes and oligodendrocytes, which populate the different brain structures, and ependymal cells will line on the ventricle surface. Thus, adult SVZ NSCs are regionally specified during the early embryonic stage and remain largely quiescent until, post-natally, they are re-activated ([@B46], [@B47]); they have intrinsic temporal programs linked to their positional characteristics (dorsal-ventral, rostral-caudal) ([@B48]) that guide differentiation in a cell-autonomous manner and cycle independently, but they also sense extrinsic cues that tune temporal programs and help indicate the 'right' time to progress ([@B49], [@B50]).

![Mouse developmental SVZ structure. Neurogenesis in humans begins with the expansion of the neuroepithelium and apical radial glia (aRG). Excitatory neurons are directly generated from apical radial glia (aRG) in the dorsal VZ or are derived from multipolar basal intermediate progenitors (bIPs) that have delaminated from the apical and basal surface and reside in the SVZ. At early stages of neurogenesis in mice, newborn deep-layer excitatory neurons move basally toward the marginal zone (MZ) by somal translocation. Once the developing cortex becomes thicker, newborn neurons reach the intermediate zone (IZ), where they undergo a multipolar-to-bipolar transition and pass through the IZ and CP. Neurons then migrate basally toward the pia, passing by earlier-born neurons; they then terminate their migration in the MZ. Inhibitory GABAergic interneurons are specified in the distant medial and caudal ganglionic eminences, where RGs, intermediate progenitors (IPs), and numerous subapical progenitors (SAPs) proliferate and migrate tangentially in two streams to integrate into the various cortical layers of the cerebral cortex (not depicted in the figure). CSF, cerebrospinal fluid; SP, subplate ([@B39]--[@B41]).](fneur-11-00148-g0001){#F1}

![Mouse developmental SGZ structure. At E14.5, in the VZ of the hippocampal neural epithelium (hNE), radial glial precursors give rise to hippocampal pyramidal neurons. The DG originates from the dentate neuroepithelium (dNE), called the primary matrix, a part of the ventricular zone (VZ). At late gestational stages, a heterogeneous mixture of stem cells and neuronal precursors at different stages of differentiation migrate from the VZ to the hippocampal fissure, constituting a new migratory progenitor population called the secondary matrix. The process is guided by hem-derived Cajal-Retzius cells. Neural progenitors reach the hippocampal fissure, where they accumulate and form a hub of proliferating cells called the tertiary matrix (SGZ). Granule cells generated during DG development from precursors of all three matrices form the GCL. By early post-natal stages, the tertiary matrix becomes the only source of dentate progenitors and granule cells ([@B39], [@B40], [@B42]).](fneur-11-00148-g0002){#F2}

The functional integrity and behavior of the niche are maintained by the extracellular membranes (ECMs) ([@B51]) of both the basal and apical sides. They are rich in laminin, αβ integrin glycoproteins, and tenascin C. Similarly, a fundamental functional role for the VZ/SVZ is played by the CSF and by the blood vessels that form in early stages of CNS development (E9) ([@B52], [@B53]). Of note, neurogenesis and angiogenesis are regulated by the same molecules, such as vascular endothelial growth factor (VEGF), Notch, and Shh ([@B54]).

In humans, similarly to rodents, during early brain development, the inner part of the neural tube that then becomes the cerebrospinal fluid (CSF)-filled ventricular structure consists of a layer of proliferative cells that originally contributes to the expansion of the cerebral cortex along with their descendant radial glia (GFAP+) and their intermediate progenitor cells ([Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). Radial glia bodies are in tight contact with the monolayer of ependymal cells that covers the ventricles ([@B57]), which serves both as barrier and transport system between the interstitial fluid of the parenchyma and the CSF ([@B58], [@B59]). Studying the behavior of human NPCs is difficult; thus, to evaluate their properties, cells from 6.5- to 9-weeks-old aborted embryonic human forebrains were expanded in culture for up to 21 passages and were transplanted into the dentate gyrus, the rostral migratory stream (RMS), the striatum, or the SVZ of adult immunosuppressed rats. Migration was modest in the dentate gyrus or in the striatum if compared to rodent-in-rodent transplant and was considered a random dispersion process during the implantation. Larger migration was observed if transplant was into the SVZ or RMS. Cells did not show tumor formation 6 weeks post-transplantation and interestingly exclusively adopted a neuronal fate when in the olfactory bulb or in the SGZ of the hippocampus ([@B60]). It is worth mentioning also that both fetal/embryonic rodent and human NPCs display regional differences in terms of proliferation and differentiation potential according to the region of the brain where they originate (cortex or striatum) ([@B61], [@B62]).

![Human fetal SVZ structure. In the developing human gyrencephalic cerebral cortex, the SVZ is subdivided by the inner fiber layer (iFL) into the inner SVZ (iSVZ) and the outer SVZ (oSVZ). Neurogenesis begins with expansion of the neuroepithelium and apical radial glia (aRG) *via* asymmetrical cell cycling. Human aRGs divide to give rise to basal RG (bRGs), which delaminate from the apical surface (retaining their basal process and attachment to the pial surface), migrate basally, and populate the oSVZ. The oSVZ is also populated by basal intermediate progenitors (bIPs) that proliferate and generate neurons. The oSVZ is the predominant germinal region in the human neocortex. The basal processes of bRG act as guides for migrating newborn neurons that disperse in the tangential axis to expand the surface area of the cerebral cortex ([@B40], [@B41]).](fneur-11-00148-g0003){#F3}

![Human fetal SGZ structure. Fetal development of the SGZ starts from the dentate neuroepithelium (dNE), which is located at the edge of the ammonic neuroepithelium (aNE) close to the fimbria. SOX1+/SOX2+ precursors are organized in ribbons between dNE and GCL (granule cell layer) already at 14 gestational weeks (GW) with PSA-NCAM and DCX positive cells. SOX1 and SOX2 cells are present in the GCL and hilus and between the GCL and the dNE. A coalesced proliferative SGZ does not form in the human DG. NeuN-positive cells are seen along with SOX1 and SOX2 at 22 GW. The cellular network reported in the illustration remains until soon after birth, when either hippocampal neurogenesis continues with aging ([@B55]) or completely disappears ([@B9], [@B39], [@B40], [@B55], [@B56]).](fneur-11-00148-g0004){#F4}

In comparison to the spatially and temporally regulated niches of the developing brain, in the post-natal and adult rodent brain, neurogenesis occurs and neural stem cells (NSCs) persist in the ventricular-subventricular zone (V-SVZ) of the lateral ventricle and in the SGZ of the dentate gyrus in the hippocampus.

Regarding the SVZ ([Figure 5](#F5){ref-type="fig"}), the population of adult NSCs is quite complex and heterogeneous, as demonstrated by single-cell sequencing data ([@B67]) and by marker-specific analysis (GFAP, EGFR, CD133, Nestin, CD9, CD81, CD24, and VEGF). NSCs of embryonic origin are called B1 cells ([@B68]), and there are roughly 7,000 in each young lateral wall of lateral ventricle. Most of the B1 cells generated between days E13.5 and E15.5 remain almost quiescent until soon after birth, when they become reactivated and start proliferating ([@B46]) or dividing very slowly ([@B63], [@B69]). NSCs divide symmetrically to self-renew or to differentiate, which leads to a decline in NSC number over time ([@B69]). B1 that face the ventricle side give rise to B2 cells, a population of fusiform-stellate proliferating V-SVZ astrocytes, that are non-neurogenic and whose function is still unknown ([@B70]). They share many astroglial characteristics with B1 cells, including contacts with blood vessels (BV), but lack contact with the apical membrane. B1 cells also generate transient-amplifying cells (type C cells) that divide symmetrically three to four times ([@B71]) and ultimately give rise to migrating neuroblasts that become young neurons (type A cells) ([@B72]). In young adult mice, B1 cells produce around 10,000 young interneurons every day that migrate for 3--8 mm along the rostral migratory stream to the olfactory bulb ([@B73]). Ventral NSCs produce deep granule cells and calbindin-positive periglomerular cells, while dorsal NSCs produce superficial granule cells and tyrosine hydroxylase-expressing periglomerular cells ([@B74]). They integrate into the existing olfactory bulb network and influence the plasticity of olfactory-related behaviors ([@B75]). B1 cells on the apical ends, which are completely surrounded by multiciliated and biciliated ependymal cells (E1 and E2 cells, respectively), which form pinwheel-like structures around them, sense the cerebrospinal fluid of the ventricle through the apical primary cilium. The choroid plexus is also considered part of the niche, and its secreted factors into the CSF regulate B1 cells. Supra-ependymal axons on the surface of the ventricular wall contact both E and B1 cells. Mature neurons and astrocytes are found below the V-SVZ ([@B63]).

![Mouse adult SVZ structure. Adult NSCs (also called radial glia-like, RGL, pre-B1 cells) of SVZ derived from embryonic radial glial (RG) cells that make neurons of the embryonic brain. The adult SVZ NSCs at embryonic day 14 (E14) upregulate p57kip2 to enter quiescence (qRGL, B1 cells). The qRGLs become activated after birth to participate in adult neurogenesis in the SVZ. In the SVZ, the RGLs mostly undergo symmetric cell division. The SVZ RGL symmetric self-renewal could occasionally also result in another type of RGL cell that lacks the apical process, named non-apical B1 cells or B2 cells. Type B1 cells give rise to neuroblast type A cells (transient amplifying cells). These young neurons are surrounded by a glial sheet and migrate anteriorly toward the olfactory bulb (OB) and differentiate in granular and periglomerular GABAergic interneurons. The adult SVZ also generates oligodendrocytes, although in much lower numbers. CSF, cerebrospinal fluid ([@B39], [@B40], [@B63]--[@B66]).](fneur-11-00148-g0005){#F5}

The number of B1 cells drastically decreases in the first year of life in mice, but the number of newborn neurons in the olfactory bulb (OB) is not significantly affected by age, suggesting that another population of NSCs that lack apical contact and that can differentiate might exist in the adult rodent brain ([@B69]). B1 cells primarily give rise to neuro-glia cells. As regards astrocytes, B1-cell ability to differentiate into astrocytes was, for example, demonstrated upon photothrombotic ischemic cortical injury ([@B76]) and upon chemical demyelination ([@B77]). Nonetheless, it has been reported that B1 cells can also give rise to oligodendrocytes ([@B78]) destined for the corpus callosum, where they myelinate axons in both healthy ([@B77]) and demyelinating conditions ([@B77], [@B79]). Although dispensable in this latter condition, they protect neurons from increased axonal loss ([@B79]). Notably, post-natal and adult neurogenesis in the SVZ is carefully controlled by microglial cells ([@B80]--[@B82]).

As regards the neural niche in the dentate gyrus ([Figure 6](#F6){ref-type="fig"}), neurogenesis occurs on the side of the granule cell (GC) layer facing the hilum, in two or three-thin strata of the SGZ. NSCs originate in the ventral hippocampus during late gestation and then re-locate to the dorsal hippocampus. Here, quiescent NSCs, called radial glia-like (rRGL, or Type 1) cells become activated (aRGL) and divide to self-renew and to make intermediate proliferating progenitors (IPCs) that then differentiate into neuroblasts. About 25% of them survive and mature into granule neurons of the DG ([@B85]) or into mature astrocytes ([@B86], [@B87]) with a strategy that still needs to be fully elucidated ([@B88]--[@B90]).

![Mouse adult SGZ structure. During the second post-natal week, proliferation in the DG becomes confined to the SGZ, where NSCs reside throughout adulthood. Genetic cell lineage tracing of Sonic Hedgehog (SHH)-responsive cells has revealed that adult NSCs are induced at peri-natal stages in a restricted region next to the most ventral side of the hippocampus in close proximity to the lateral ventricle. From there, they migrate to populate all regions of the DG. Thus, embryonic and adult NSCs in the DG have different origins. Indeed, the generation of new neurons in the DG starts from radial glia-like progenitor (type I). Type I cells become activated. Activated type I cells generate intermediate progenitors (type IIa, ab, and b and type III). Type III converts into immature granule cells and finally into mature long-lasting calbindin/calretinin-positive granule cells. IML, inner molecular layer; GCL, granule cell layer. Nicola et al. showed that a condensed germinal zone in SGZ only appears during post-natal days 7--14, likely because it depends on neural activity for adult neurogenesis established by the SVZ ([@B83]). A recent report suggests that a dentate-specific neural progenitor, arising in mice at \~E11.5 and marked by *Hopx* positivity, persists from embryonic development to adulthood. These progenitors give rise at E18.5 and P7 to the dentate region and then transition to quiescence early post-natally, to contribute to neurogenesis only during the adult lifespan. Those RGLs might have limited capacity for self-renewal, are skewed toward neurogenic differentiation, and rarely make astrocytes ([@B40], [@B42], [@B65], [@B84]).](fneur-11-00148-g0006){#F6}

While in the SVZ NSCs mainly give rise to inhibitory interneurons, in the DG, they generate new excitatory neurons that are involved in learning, memory, and pattern separation ([@B91]). New-born neurons of the SGZ are mainly located in the GC layer and do not migrate. Further, while in the SVZ, depending on the position, progenitors develop toward a different fate, the neural progenitors of the SGZ present only a bipotential fate ([@B6]). The two neurogenic niches face a 50--70% death rate during the first few days of birth, and short-living new-born neurons not only have different electrical properties than mature ones but may have their own functional role ([@B39]).

In both adult mouse neurogenic niches, it has also been reported that stem cells and differentiated daughter cells act to regulate their respective maintenance. For example, differentiated neurons release diffusible or contact-mediated signals, such as the neurotransmitter GABA and the Notch ligand Delta-like 1 (Dll1), which help to maintain NSC quiescence ([@B92], [@B93]). On the other hand, Tang C. and coworkers recently demonstrated a feed-forward mechanism between NSCs and newly generated neurons through pleiotrophin (PTN) ligand, whose release by NSCs supports the development of the newly differentiated neurons ([@B94]). Down the line, this cross-talk might impact the important role of striatal neurons in cognitive functions and goal-directed behavior (the dorsomedial striatum, DMS) ([@B95]), as well the sensorimotor territory and habit formation \[the dorsolateral striatum (DLS)\] ([@B96]).

In humans, post-natal SVZ ([Figure 7](#F7){ref-type="fig"}) is different from in other mammals because it consists of a smaller inner and expanded outer SVZ (iSVZ and oSVZ, respectively). The oSVZ contains radial glia that support neurogenesis and cortical expansion during fetal development ([@B98]). After corticogenesis, the neurogenic niche of the iSVZ and oSVZ remains proliferative in neonates along the wall of the lateral ventricle in the site of former lateral ganglionic eminence, generating new neurons that populate the pre-frontal cortex and, partially, the olfactory bulb ([@B81], [@B99]) for a few months after birth. Subsequently, however, this activity declines dramatically, and, within 2 years, there is almost no detectable neurogenesis or migration ([@B100]--[@B103]). Perinatally, SVZ stem cells differentiate and migrate along three specific pathways toward the anterior forebrain: (i) to the frontal lobe where they become interneurons (arc pathway) ([@B103]); (ii) to the medial pre-frontal cortex along the medial migratory stream (MMS); (iii) to the olfactory bulb along the RMS ([@B104]). Moreover, while in many mammals newly SVZ-generated neurons migrate specifically to the olfactory bulb to guarantee olfaction throughout life ([@B105]), in the human frontal cortex, only inhibitory neurons are born post-natally with unclear function or contribute to neurocognitive maturation and plasticity, important in infancy ([@B103], [@B106]).

![Human adult SVZ structure. The human adult SVZ consists, from the ventricle side to the parenchima, of Layer I of multicyliated ependymal cells, with radial and tangential processes, followed by a hypocellular layer (Layer II) of astrocytic and neuronal cell bodies with a number of cytoplasmic expansions of ependymal cells inserted by astrocytic ramifications. Layer III consists of a ribbon of proliferative astrocytes (type B cells). Some oligodendrocyte-like precursors and misplaced ependymal cells are found. The inner layer (Layer IV) consists primarily of myelin tracts and neuronal bodies. SEZ, sub-ependymal zone; CSF, cerebrospinal fluid ([@B39], [@B40], [@B97]).](fneur-11-00148-g0007){#F7}

Mature, adult human SVZ consists of four layers. Moving from the ventricle side, Layer I consists of ependymal cells in contact with the lumen, and this is followed by an almost acellular layer (Layer II), which originates post-natally as a consequence of neuroblast depletion. This layer includes a dense network of astrocytes and ependymal cell processes, where astrocytes and ependymal cells exchange signaling, and the few microglial cells influence communication among the cell types ([@B107]). Adjacent to Layer II, there is a dense rim of astrocytic cell bodies (Layer III) with variable morphology. Finally, Layer IV consists of a transitional region with few cells, similar to the brain parenchyma. Although some astrocytes can proliferate ([@B99], [@B108]), neuroblasts are absent in the adult human SVZ niche and in the rostral migratory stream toward the olfactory bulb ([@B101]). Interestingly, in the adult human brain, newly generated cells are mainly oligodendrocytes, not neurons ([@B109]), suggesting that the oligodendrogenic process and myelin maintenance is more important in the human brain compared to other mammals.

Of note, comparing mouse and human adult SVZ, the proportion of type A:B:C cells in the mouse brain is 3:2:1, while in human, it is estimated at 1:3:1 ([@B110]).

Besides the differences between embryonic and adult niches, we have already anticipated that the niche changes during development. Indeed, a general comprehensive analysis of NPCs in mice from post-natal age P7 and P28 revealed not only that the number of NPCs decreases over the course of development but also that the genetic profile of the NPCs at the two ages was significantly different, suggesting early adulthood senescence ([@B111]).

Interestingly, it has been shown that neurons born during embryonic development (E19) and early adolescence (P21) (in mice) survived throughout adulthood (up to 2--6 months), while the cells generated at P6 displayed 15% cell death during adulthood, suggesting that early post-natal granule cells have an important unique function in terms of hippocampal plasticity ([@B112]). Early-life post-natal hippocampal neurogenesis is crucial to strengthen the ability to learn and to acquire new information via a rapid and continuous generation of new granule cells at the expense of existing memories and information storage.

Moreover, a recent report in mice showed that a population of NSCs exists in the DG that contributes to neurogenesis throughout development and adulthood and that the NSCs shift from a quiescent to an active state at different time points ([@B84]), suggesting that hippocampal neurogenesis is crucial for maintaining tissue plasticity. Indeed, the technology of single-cell RNA sequencing demonstrated that while there is an early post-natal transformation of radial glia cells from embryonic progenitors to adult quiescent stem cells maintained as such through adulthood, intermediate progenitor cells, neuroblasts, and immature granule cells are very similar at all ages ([@B113]).

Although the evidence that progenitor cells exist in the human brain is robust ([@B114], [@B115]) ([Figure 8](#F8){ref-type="fig"}), controversies still persist about *in vivo* evidence that neurogenesis occurs in the adult hippocampus and about its functional relevance. A first landmark study on autoptic human brain tissue measured the concentration of ^14^C in genomic deoxyribonucleic acid (DNA) and estimated that 700 new neurons are generated each day in the adult human hippocampus corresponding to an annual turnover of 1.75% ([@B118]), comparable to what is seen in middle-aged rodents.

![Human adult SGZ structure. Based on the report by Boldrini et al. neurogenesis persists during adulthood. The generation of new neurons starts from quiescent radial glia-like progenitor cells (type I). Type I cells become activated and then, by asymmetric division, generate intermediate progenitors (type II). Type II become neuroblasts or intermediate neural progenitors (INP type III) that convert into immature granule cells and finally mature into long-lasting granule cells that send their apical processes to the CA3 part of the hippocampus. On the other hand, according to Sorrells et al. neurogenesis is not detected in adult. In the dentate gyrus, a proliferative subgranular zone (SGZ) is not formed near the granular cell layer, and proliferative progenitor stem cells are scattered in the hilus only. They disappear anyway after 7 years from birth, and young neurons are not found in adult individuals. Curly brackets define the condition described in Sorrells et al. ([@B9], [@B39], [@B40], [@B55], [@B56], [@B64], [@B116], [@B117]).](fneur-11-00148-g0008){#F8}

In this process, aging, an altered immune-related molecular and cellular status, is the most critical environmental driver that can impair neurogenesis and contribute to its decline. Indeed, when heterochronic parabiosis was attempted by exposing aged animals to a young systemic environment, adult neurogenesis increased through a-yet unknown precise mechanisms ([@B119], [@B120]). Moreover, Spalding et al. showed that neurogenesis also occurs in the human hippocampus in older age, in contrast to the age-related decline previously described in rodents ([@B121]). Similarly, another group observed immature and mature adult-born neurons in hippocampal post-mortem samples of healthy adult individuals ([@B55]). This evidence has recently been replicated by Moreno-Jiménez et al. who described the presence of immature neurons in the DG of 90-years-old human subjects ([@B122]) and by Tobin et al. who demonstrated that hippocampal neurogenesis occurs in the tenth decade of life ([@B123]). In contrast, a study on peri- and post-natal human samples from subjects with a wide range of diseases reported few young neurons in young individuals (7--13 years of age) and no newborn neurons in the DG of adults. Immature neurons were found only in specimens of 1-year-old subjects ([@B56]). Divergences between mouse and human are likely due to differences in the rate of generation and maturation of newborn neurons ([@B124]), while divergences among human studies might depend on limitations when using human post-mortem tissues to study neurogenesis with variable time from death to fixation.

Features of Plasticity in Neural Stem Cells {#s4}
===========================================

NPCs, because of their intrinsic stem nature, exploit several plastic features. We have already mentioned their dual cell division capacity, symmetric and asymmetric, their capacity to stay quiescent in the niche for a long time and then to be activated/proliferate and to differentiate, and their regional differences, as well as their capacity to sense the environment ([@B125]) and promote neuro-biochemical changes ([@B94]). The brain is substantially a "non-renewable organ," and brain cells slowly die with age, but neural stem cells guarantee to the CNS a certain ability to reorganize structurally and function according to intrinsic and environmental demands ([@B126]). Although proliferation and differentiation occur, it is still debated whether endogenous adult NSCs really exhibit long-term self-renewal capacity.

Encinas and collaborators reported that in the SGZ, NPCs can proliferate and then differentiate into astrocytes but that this causes progressive pauperization of the niche without returning to quiescence ([@B127]). Bonaguidi et al. instead showed, via clonal analysis, that NPCs face repetitive rounds of activation followed by astrocyte differentiation and quiescence ([@B6]). Unfortunately, different genetic labeling strategies target different populations of NSCs and different activation states of the same population, providing still complex and partial results.

Another plasticity feature for NPCs is related to the intrinsic tri-lineage potential of endogenous NSCs in the adult mammalian brain. However, although *in vitro* in culturing conditions, NSCs, both human and mouse, give rise to three different cell types, time-lapse analysis revealed generation of either neurons or oligodendrocytes, not both ([@B128]). Vice-versa, *in vivo*, different reports are available: population fate mapping has described that SVZ-NSCs generate neurons and astrocytes, not oligodendrocytes ([@B6]), while clonal analysis has recently indicated that only neuronal lineages are generated from individual NSCs ([@B129]). Cell commitment could derive from a progressive restricted lineage profile occurring in the adult ([@B130]). According to an alternative hypothesis, the trilineage potential is shaped and maintained by the niche environment ([@B131]).

The possibility that precursor cells can make new neurons is important for their therapeutic potential in neurodegenerative conditions. This potentiality has been exploited in preclinical models for stroke ([@B132], [@B133]). Unfortunately, after stroke, only few neuroblasts survive and differentiate, migrating from the SGZ into the granule cell layer to form novel neural circuits ([@B134]); these are not numerous enough to recover neurologic functions under ischemic conditions, and only 0.2% of lost neurons are replaced ([@B135]). Therefore, enhancing proliferation, survival, and neuronal maturation of endogenous or transplanted NSCs is important for brain disorders. Of note, while in animal models of neurodegenerative diseases like stroke, depression, epilepsy, Alzheimer\'s, Huntington\'s, and Parkinson\'s diseases, as well as in affected humans, progenitor cell proliferation and neurogenesis occur in the SGZ (at a lower rate in the latter and depending on the disease), in human, the SVZ is particularly sensitive to neurodegeneration and more responsive than SGZ via proliferation ([@B136]).

Under physiological conditions, the plasticity of NPCs is exploited for brain development, learning, and memory ([@B137], [@B138]) and is mediated by the release of trophic factors. This feature is fundamental during neurogenesis; it is important to tune synapse connections and to modulate neuronal networks during healing processes after brain injuries. Synaptic connectivity is indeed mediated by released neurotrophins (NTs), such as brain-derived neurotrophic factor (BDNF), NT-3, and NT-4 ([@B139], [@B140]). Depending on the type and concentration, they strengthen or weaken synaptic morphology ([@B141]) and synaptic responses ([@B142]), leading to long-term potentiation (LTP) or long-term depression (LTD). Moreover, they can form new connections and pathways and can change the wiring of the circuits ([@B143]). In severe pathological conditions, physiological trophic effects will not provide sufficient tissue regeneration. However, engraftment of exogenous stem cells, via the release of neuroprotective, trophic, or immunomodulatory factors, may stimulate endogenous neurogenesis, angiogenesis, and neovascularization, helping in the healing processes ([@B144]) and promoting the formation of new pathways around damaged tissue. The mechanism is active in the perinatal period and early-childhood, but it is progressively reduced in the brains of older children and adult individuals ([@B145]).

Cell therapy could be more beneficial when stem cells are engineered ([@B146], [@B147]). For example, elevated NT-3 expression can provide a microenvironment favorable to the survival and differentiation of transplanted neural stem cells ([@B148]).

For many (if not all) of the features above mentioned, epigenetic regulation plays an important role in shaping the response to the environmental cues of NPCs, depending on their developmental stage ([@B149], [@B150]).

The plasticity of NPCs is also exploited by their capacity to interact with scaffolds, as detailed below in the Spinal Cord Injury (SCI) section.

Therapeutic Applications {#s5}
========================

Leveraging their plasticity, NPCs have been proposed for (i) neurotoxicity testing, (ii) cellular therapies to treat CNS conditions, (iii) neural tissue engineering and repair, (iv) drug target validation and testing, and (v) personalized medicine, as detailed below.

Since the developing CNS is more vulnerable to chemical exposure, *ad hoc* pharmacological testing is required ([@B151]). To address this goal, NSCs turned out to be useful for neurotoxicity testing. Developmental Neurotoxicity (DNT) is indeed a function not only of the type of exposure (dose, duration) but also of the developmental stage of the brain at the time of exposure ([@B152]). The blood--brain barrier (BBB) is not completely formed until at least 6 months after birth, facilitating the entrance of a chemical into the fetal/neonatal brain ([@B153]). Considering the increase of children\'s neurodevelopmental impairments \[e.g., learning disabilities, autism, attention deficit hyperactivity disorder (ADHD)\], likely due to exposures to chemicals with DNT potential, concerns have been raised about the need to identify suitable tools to properly ascertain drug toxicity. Assessment has been primarily based on animal studies, but the tests are very resource-intensive in terms of animals, time, and costs ([@B154], [@B155]), underlining the need to develop alternative approaches to identify DNT. *In vitro* work has been performed using rodent and human neuronal and glial cellular models (neuroblastoma cell lines) to evaluate (via dose-response relationships) the impact of a compound on various stages of brain development. Unfortunately, transformed/immortalized cell lines present limitations, such as the expression of proliferating genes that impact cellular response to chemical exposure ([@B156], [@B157]). On the other side, human *in vitro* neuronal cultures derived from neural progenitor cells (NPCs) or brain fetal NPCs grown as neurospheres can better mimic critical brain developmental processes, including proliferation, apoptosis, migration, and differentiation ([@B158]). However, as already mentioned, the ethical issues regulating the generation and use of human embryonic or fetal-derived tissues have been a matter of intense debate. Therefore, hiPSC-derived neuronal and glial models have been proposed for their applicability in *in vitro* pharmacological and toxicological studies. Indeed, human iPSC-derived cultures of mixed neuronal and glial cells are suitable for DNT, actually more so than for adult neurotoxic evaluation ([@B159]) because hiPSC-derived cells (and hESCs) reproduce in a more difficult way the terminal differentiation and the functional characteristics of adult brain physiology even after long term culture ([@B160]). Moreover, hiPSC-derived NPCs have an earlier neurodevelopmental phenotype because, instead of differentiating in culture into Nestin and GFAP+ like primary human NPCs, they express TubβIII ([@B161]).

Current efforts in the context of hiPSCs to optimize culturing and differentiation protocols are on-going to better mimic the brain context using defined factors and co-culture conditions. The generation of microglia-like cells from hiPSCs has helped to introduce the immune component into neuroglia culture ([@B162]--[@B166]). Further, hiPSCs have also been differentiated into brain endothelial cells that mimic the functionality of the BBB *in vitro*, adding further value to their use in DNT tests ([@B167]). Additionally, three dimensional (3D) culture and cerebral organoids have been developed and can recapitulate brain region connections occurring *in vivo* in the cerebral cortex ([@B168]). Assessing endpoints in 3D systems will be critical for guaranteeing the applicability of hiPSCs for DNT in complex assays. Combining *in vitro* DNT tests with *in vivo* epidemiological human data is crucial for developing Integrated Approaches to Testing and Assessment (IATA) for regulatory purposes (chemical screening, hazard identification/characterization, or risk assessment) ([@B169]).

NPCs surely play a crucial role in CNS tissue repair, and their intrinsic plastic nature gives them therapeutic potential in neurological diseases via two Modes of Action (MoA)L cell replacement and the bystander effect.

As regards cell replacement, NPCs are, in principle, a suitable therapeutic strategy for those diseases in which neurodegeneration and cellular loss are prevalent, not only because they mediate cell replacement but also because they can re-establish and/or support neuro-glial functional connections lost during the pathological process. This approach was tested decades ago, for example with fetal NSCs ([@B170]) transplanted into subjects with Parkinson\'s disease, and recently with hiPSC-derived cortical precursors transplanted into an Alzheimer\'s mouse model ([@B171]). However, in the first case, transplanted stem cells or progenitors could not survive for long or form the desired cell types. In the second case, human cells reproduced the pathological phenotype of AD neurons, influenced by the genetic background they had been transplanted into, suggesting that the NPC cell replacement strategy is promising only when extrinsic inflammatory neurodegenerative factors have faded in the CNS site where transplant occurs or for cell-autonomous neurological disorders. In general, transplanted NPCs give rise to the atypical ectopic perivascular niche with intense cell-to-cell cross-talk between transplanted NPCs and resident cells. NPCs may either remain in the niche in an undifferentiated state or move to acquire a terminally differentiated phenotype ([@B172], [@B173]) and adapt their fate according to the region of engraftment, developing neuronal or glial markers ([@B174]--[@B176]). For example, transplanted NPCs have been shown to form functional gap junctions to rescue host neurons and their projections in an animal model of Purkinje neurodegeneration ([@B177]). Moreover, human iPSC-derived NPCs have been shown to engraft and establish long-distance connections in animal models ([@B178], [@B179]), although concerns on the approach are still under evaluation (see below). It is crucial to mention the importance of homotopic rather than heterotopic transplantation to avoid tumorigenic risk, since region-specific cues instruct the grafts of NSCs ([@B180]). So far, this has been the predominant strategy.

Besides this evidence, NPCs might protect the CNS through mechanisms alternative to direct cell replacement, which implies the interaction of NPCs with both resident neural and immune cells. Indeed, transplanted NPCs rather exert immunomodulatory or neuroprotective functions modulating the response of the pathological processes of astrocytes, microglia, and inflammatory blood-born cells through paracrine and endocrine mechanisms (bystander effects). NPCs, upon interaction with CNS-resident cells, start releasing neurotrophic factors, such as Nerve Growth Factor-NGF, BDNF, and Glial Derived Neurotrophic Factor-GDNF, along with reactive species, binding proteins, purines, or cytokines that might significantly reduce scar formation and/or increase the survival and function of endogenous glial and neuronal progenitors. This was originally demonstrated in mice with primary inflammatory disorders, including the animal model of MS ([@B173], [@B181]) or stroke ([@B182], [@B183]) and in mice with neurodegenerative diseases mediated by reactive inflammation, such as Parkinson\'s Disease ([@B184]). Those properties have been then described for other stem cells, such as mesenchymal stem cells ([@B185]). The concept that therapeutic effect derives from released molecules opened the possibility of using the "secretome" of stem cells, which implies a cell-free therapeutic approach ([@B186]--[@B191]). The cross-talk with the environment is fundamental for promoting the release by NPCs of a context-specific arsenal of biological weapons, and the impact of external cues on paracrine signaling has been widely described recently ([@B186], [@B192]--[@B197]). However, most of the environmental cues that trigger the production of bioactive and restorative factors and the mechanisms they elicit in a specific disease are still unknown. Therefore, triggering *in vitro* the production of biologics and collecting and using the secreted factors, although promising, remains a reductionist approach, and efforts to efficiently transplant cells that sense and respond *in situ, ad hoc* to the environment are still most appropriate.

The immunomodulatory function is a feature of human NPCs ([@B198], [@B199]) that enables them to inhibit T-lymphocyte proliferation as well as dendritic cell maturation *in vitro*, to ameliorate disease severity when transplanted systemically in non-human primates with EAE, and to persist long-term, not only in the host CNS but also in peripheral lymph nodes ([@B200]). NPCs show pathotropism for the pathological sites, thanks to the expression of chemokine receptors, cell adhesion molecules, and integrins. Once transplanted (intravenously, i.v., or intrathecally, i.t.) and after migration into inflamed CNS areas, NPCs do no significantly differentiate but survive in close proximity to blood vessels, where they interact with CNS-infiltrating blood-derived inflammatory cells, endothelial cells, and CNS-resident astrocytes and microglia, releasing therapeutic molecules ([@B201]). In diseases characterized by primary inflammation, such as MS, stroke, or spinal cord injury, a precise control of time and route of cell administration is important to gain the therapeutic effect because NPCs transplanted in immunocompetent mice can be rejected in animals with ongoing neuroinflammation ([@B202]), and the immunomodulatory and trophic support might have a limited effect. Nonetheless, early NPC transplantation is important because, immediately after CNS damage, genes supporting tissue growth predominate over genes promoting anti-plasticity and differentiation ([@B203]).

Examples of NPC cell replacement and bystander effects for some diseases are detailed below.

Ischemic Stroke
---------------

Stem cell transplantation for stroke has represented a valuable therapeutic strategy using various sources of NSCs. Human ESC-derived NPCs have been implanted in rodents after cerebral ischemia, and they have shown neural differentiation and improved functional recovery ([@B204], [@B205]). Moreover, transplanted and engrafted NSCs (i) reduced cell death and inflammation near the graft ([@B182]) and promoted angiogenesis ([@B206]); (ii) promoted proliferation and neuronal differentiation of endogenous NSCs of the subventricular and hippocampal subgranular zone in rodents ([@B135]), primates ([@B207]), and humans ([@B208], [@B209]); (iii) survived to intracerebral transplantation in lesioned brain and differentiated into mature neurons ([@B178]), integrating in host neuronal circuitry to promote post-stroke morphological and electrophysiological recovery ([@B20]), although several months later.

A key aspect for clinical applications of exogenous NPCs is the route of administration, which can be: (i) intraparenchymal, implying direct injection of the cell suspension close to the site of injury; this strategy achieved motor and cognitive improvements in grafted patients ([@B210], [@B211]), or (ii) intravascular, which is used in a limited number of trials because it is more suitable for mesenchymal stem cells. Although a greater number of cells can be administered, unfortunately, the majority does not migrate to the brain ([@B212]). Moreover, this approach retains a risk of tumorigenicity due to the possibility of heterotopic graft ([@B180]).

Since NSC transplantation in preclinical stroke models was able to promote the proliferation of endogenous NSCs and the migration of endogenous neuroblasts to the damaged brain region where they differentiate into mature neurons ([@B213]), activation of endogenous NPCs for remodeling neural tissue after ischemic injury has also been considered as a therapeutic strategy because it would not require transplantation of exogenous cells and would avoid annexed risks of introducing exogenous pathogens and of enhancing CNS immune surveillance, inflammatory reactions, and tissue rejection, as well as bypassing political and ethical concerns. In this perspective, treatment of stroke conditions with growth factors, such as epidermal growth factor (EGF) and fibroblast growth factor (FGF) promoted the recruitment of endogenous NPCs and regenerated hippocampal circuitry, restoring synaptic function after ischemia ([@B214]).

The option of using NSCs from iPSC in stroke in human is a bit more complicated to implement, due to the advanced age of most stroke patients, making it very difficult to efficiently generate iPSCs from aged subjects that can be used to perform autologous transplant. Moreover, although in some stroke models they have shown efficacy ([@B215]), it remains questionable whether iPSCs derived from aged patients are beneficial for post-stroke functional recovery ([@B216], [@B217]).

A phase 1 study on stroke subjects using the CTX0E03 or ReN001 cell line (ReNeuron) derived from genetically modified human fetal neuroepithelium has been conducted ([@B211]). c-mycERT AM technology was used to drive the expression of an estrogen receptor under tamoxifen (4-OHT) (in culture conditions) to control cell proliferation. Cell division was indeed arrested, and differentiation into neuronal and glial lineages was induced by removal of tamoxifen and of growth factors from the medium. Eleven men were enrolled; they did not receive any immunosuppressive therapy and were followed for 2 years. While immunological or severe adverse effects were not recorded, modest improvements on the different motor scales were observed \[NIHSS, Barthel index, Ashworth Spasticity Scale for the arm and leg, and a quality-of-life and health status questionnaire, EuroQoL Five Dimensions (EQ-5D)\].

Spinal Cord Injury (SCI)
------------------------

NPCs have also been intensively studied and their use proposed as a therapeutic strategy for traumatic spinal cord injury, despite the complexity of the pathology ([@B218]).

NPCs have the potential to repopulate severely injured spinal cord ([@B197], [@B219]), but their ability to survive and reconstitute neural tissue and neural connections remains limited by parenchyma loss and by the very toxic milieu ([@B220]). Moreover, the epicenter of the primary lesion site rapidly become necrotic, so NPCs may need an extracellular skeleton to support survival and guide tissue reorganization. Biomaterials represent a suitable support for cells, replacing the extracellular matrix to favor cell survival, differentiation, re-vascularization, and re-colonization of the tissue by glial and endothelial cells. Moreover, complex biomimetic materials that can be produced may guide axonal growth, restoring long-distance connections. More preclinical research in this innovative field is definitely required. Regenerative compounds, biomaterials, and tissue, along with cellular transplants, have been used for SCI to enhance neurite outgrowth and facilitate tissue regeneration ([@B221]). Indeed, three-dimensional highly porous "scaffolds" made of biodegradable copolymers have been tested and seeded with NPCs into the lesion to facilitate donor cell survival, migration, differentiation, functional structural repair, and neural circuit activation ([@B222]). Recently it has been reported that NPC-mediated functional recovery could depend on oligodendrocyte differentiation ([@B223]). Although NPCs have been quite extensively tested in SCI preclinical models, improvement for patients is still limited. Okano\'s team in Japan started a human clinical study using allogenic iPSC-derived NPCs because costs, quality testing, safety concerns, and time were not compatible with autologous transplants. Nonetheless, when immunosuppression was stopped, complications arose. Thus, so far, only autologous iPSC-derived NPCs hold promise for repair of the injured spinal cord ([@B224]).

Neurodegenerative Diseases
--------------------------

NSCs may be delivered by three different routes: intravenous, intraparenchymal, or intra-cerebroventricular via lumbar puncture injection. Preclinical data have shown that via intraparenchymal delivery, NSCs migrate and spread along the corpus callosum, driven by tissue-specific disease factors ([@B225]). Via intravenous injection, NPCs cross the inflamed BBB, reaching the demyelinating areas of the CNS in animal models of multiple sclerosis (EAE) and eliciting therapeutic actions ([@B172], [@B200]), although NPCs could exert their bystander immunomodulatory effect also systemically. NPCs represent an effective therapeutic tool in multifocal, primary inflammatory diseases, such as multiple sclerosis, being able to migrate and exploit their bystander effect. Currently, the preclinical results in the MS context have been translated to the clinic using fetal NPCs (NCT03269071) in primary progressive MS subjects. fNPCs are currently used as a therapeutic choice also for other neurodegenerative diseases ([@B225]), and several clinical trials are in progress for neurodegenerative diseases, such as Parkinson\'s disease, ALS, tumors, and various pediatric diseases (not reported).

[Table 1](#T1){ref-type="table"} summarizes the ongoing non-pediatric clinical trials selected on [clinicaltrials.gov](https://www.clinicaltrial.gov) by using the key terms "neural stem cells," and "neural progenitor cells." Around 30 clinical trials reporting on transplant of NSCs have been registered on [clinicaltrial.gov](https://www.clinicaltrial.gov).

###### 

List of clinical trials using NPC/NSC in adult subjects.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Disease**                                **Title**                                                                                                                                                                             **Trial phase**   **N^**°**^ patients**   **Age**                     **Follow-up (months)**   **Cell type**                                              **Site and mode of administration**                    **Sponsor**                                        **NCT Number**   **Status**
  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------------- --------------------------- ------------------------ ---------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------- ---------------- -------------------------
  Age-Related Macular Degeneration           Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)                                                                                 Phase 1\          15                      \>50                        12                       Human neural stem cell                                     Subretinal space (injection)                           StemCells, Inc.                                    NCT01632527      Completed
                                                                                                                                                                                                                                   Phase 2                                                                                                                                                                                                                                                                              

  Amyotrophic Lateral Sclerosis              Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (hNSCALS)                                                                                                     Phase 1           18                      20--75                      36                       Human fetal neural stem cell                               Lumbar spinal cord (surgical device)                   Azienda Ospedaliera Santa Maria, Terni, Italy      NCT01640067      Completed

  Amyotrophic Lateral Sclerosis              CNS10-NPC-GDNF for the Treatment of ALS                                                                                                                                               Phase 1           18                      \>18                        12                       Human neural stem cell                                     Lumbar spinal cord (stereotactic device)               Cedars-Sinai Medical Center                        NCT02943850      Active, not recruiting

  Amyotrophic Lateral Sclerosis              Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis                                     Phase 2           18                      \>18                        24                       Human neural stem cell                                     Spinal cord (injection)                                Neuralstem Inc.                                    NCT01730716      Unknown status

  Amyotrophic Lateral Sclerosis              Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)                                                                   Phase 1           18                      \>18                        48                       Human neural stem cell                                     Lumbar spinal cord (surgical implant)                  Neuralstem Inc.                                    NCT01348451      Unknown status

  Brain Tumors                               Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients with Recurrent High-Grade Gliomas                                                           Phase 1           18                      \>18                        always                   Human neural stem cell                                     Intracranial                                           City of Hope Medical Center                        NCT02015819      Active, not recruiting

  Brain Tumors                               A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing *E. coli* Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas   Phase 1           15                      \>13                        always                   Human neural stem cell                                     Debulking craniotomy                                   City of Hope Medical Center                        NCT01172964      Completed

  Brain Tumors                               Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma                                                                                                                Phase 1           36                      \>18                        NA                       Induced neural stem cells                                  Intracranially                                         Northwestern University                            NCT03072134      Recruiting

  Brain Tumors                               Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients with Recurrent High-Grade Gliomas                                          Phase 1           53                      18--69                      180                      Human neural stem cell                                     Intracranial                                           City of Hope Medical Center                        NCT02192359      Recruiting

  Ischemic Stroke                            Pilot Investigation of Stem Cells in Stroke Phase II Efficacy (PISCES-II)                                                                                                             Phase 2           23                      \>40                        12                       Human neural stem cell                                     Intracerebral                                          ReNeuron Limited                                   NCT02117635      Completed

  Ischemic Stroke                            Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke                                                                                               Phase 1           18                      30--65                      24                       Human neural stem cell                                     Intracranial injection                                 Suzhou Neuralstem Biopharmaceuticals               NCT03296618      Active, not recruiting

  Ischemic Stroke                            Investigation of Neural Stem Cells in Ischemic Stroke (PISCES III)                                                                                                                    Phase 2           110                     35--75                      12                       Human neural stem cell                                     Stereotactic injection                                 ReNeuron Limited                                   NCT03629275      Recruiting

  Ischemic Stroke                            A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke                                                                                                                        Early Phase 1     12                      30--65                      12                       Induced neural stem cells                                  Intracerebral Transplantation                          Allife Medical Science and Technology Co., Ltd.    NCT03725865      Not yet recruiting

  Parkinson\'s Disease                       A Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson\'s Disease Patient (hNSCPD)                                                                      Phase 2\          12                      35--70                      6                        Human fetal stem cell                                      Nasal injection                                        Second Affiliated Hospital of Soochow University   NCT03128450      Unknown status
                                                                                                                                                                                                                                   Phase 3                                                                                                                                                                                                                                                                              

  Parkinson\'s Disease                       A Study to Evaluate the Safety of Neural Stem Cells in Patients with Parkinson\'s Disease                                                                                             Phase 1           12                      30--70                      12                       Induced neural stem cells                                  Intracerebrally to the striatum and substantia nigra   Cyto Therapeutics Pty Limited                      NCT02452723      Active, not recruiting

  Parkinson\'s Disease                       A Study on the Treatment of Parkinson\'s Disease with Autologous Neural Stem Cells                                                                                                    Early Phase 1     10                      18--60                      12                       Induced neural stem cells                                  NA                                                     Allife Medical Science and Technology Co., Ltd     NCT03815071      Not yet recruiting

  Parkinson\'s Disease                       Transplantation of Neural Stem Cell-Derived Neurons for Parkinson\'s Disease                                                                                                          Phase 1\          12                      35--85                      6                        Human neural stem cell                                     Basal ganglia                                          NeuroGeneration                                    NCT03309514      Not yet recruiting
                                                                                                                                                                                                                                   Phase 2                                                                                                                                                                                                                                                                              

  Parkinson\'s Disease                       Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson\'s Disease                                                                        Phase 1\          50                      50--80                      12                       Human embryonic stem cell-derived neural precursor cells   Intra-striatal injection                               Chinese Academy of Sciences                        NCT03119636      Recruiting
                                                                                                                                                                                                                                   Phase 2                                                                                                                                                                                                                                                                              

  Pelizaeus-Merzbacher Disease (PMD)         Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects with Connatal Pelizaeus-Merzbacher Disease (PMD)                                                               Phase 1           4                       Child, Adult, Older Adult   4                        Human neural stem cell                                     Brain                                                  StemCells, Inc.                                    NCT01391637      Completed

  Peripheral Arterial Disease                Safety Trial of CTX Cells In Patients With Lower Limb Ischemia                                                                                                                        Phase 1           5                       \>50                        12                       Human neural stem cell                                     Gastrocnemius muscle                                   ReNeuron Limited                                   NCT01916369      Completed

  Progressive Multiple Sclerosis             Neural Stem Cell Transplantation in Multiple Sclerosis Patients (STEMS)                                                                                                               Phase 1           12                      18--55                      24                       Human fetal-derived Neural Stem Cells                      Intrathecal                                            IRCCS San Raffaele                                 NCT03269071      Enrolling by invitation

  Secondary Progressive Multiple Sclerosis   Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients (NSC-SPMS)                                                                   Phase 1           24                      18--60                      12                       Human neural stem cell                                     Intraventricular                                       Casa Sollievo della Sofferenza IRCCS               NCT03282760      Active, not recruiting

  Spinal Cord Injury                         NeuroRegen Scaffold, Combined with Stem Cells for Chronic Spinal Cord Injury Repair                                                                                                   Phase 1\          30                      18--65                      24                       Human neural stem cell                                     Spinal cord (injection)                                Chinese Academy of Sciences                        NCT02688049      Enrolling by invitation
                                                                                                                                                                                                                                   Phase 2                                                                                                                                                                                                                                                                              

  Spinal Cord Injury                         Long-Term Follow-Up of Transplanted Human Central Nervous System Stem Cells (HuCNS-SC) in Spinal Cord Trauma Subjects                                                                 NA                12                      18--65                      NA                       Human neural stem cell                                     Intramedullary spinal cord transplantation             StemCells, Inc.                                    NCT01725880      Terminated

  Spinal Cord Injury                         Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI (SCI)                                                                     Phase 1           8                       18--65                      54                       Human neural stem cell, spinal cord derived                N/A                                                    Neuralstem Inc.                                    NCT01772810      Recruiting

  Spinal Cord Injury                         Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients with Thoracic Spinal Cord Injury                                                                              Phase 1\          12                      18--60                      48                       Human neural stem cell                                     Intramedullary transplantation                         StemCells, Inc.                                    NCT01321333      Completed
                                                                                                                                                                                                                                   Phase 2                                                                                                                                                                                                                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The therapeutic plasticity of NSCs has been exploited in the specific context of neural tissue engineering and repair. The development of safe techniques to generate autologous NPCs (iPSC technology and direct reprogramming of somatic cells) opened up novel therapeutic opportunities in the regenerative field. In particular, directly reprogrammed Neural Precursor Cells (drNPCs) ([@B226]) are non-immunogenic and have a stable genome and minimal risk of malignant transformation, if compared to induced-pluripotent and embryonic stem cells, while exhibiting self-renewal and multipotency.

To increase the therapeutic potential of NSCs and analogs, combination therapy of cells with engineered and miniaturized scaffolds improved spinal motor functions, as reported in a meta-analysis of more than 70 preclinical studies ([@B227]), and transplantation with tissue-engineered constructs outperformed the efficiency of suspended cells alone ([@B228]). Similarly, there has been recent testing of a "liquid matrix" strategy, which is based on platelet-rich plasma (PRP)-derived hydrogel on a solid anisotropic complex scaffold prepared using a mixture of recombinant analogs of the spider dragline silk proteins which significantly stimulated proliferation and neuronal differentiation ([@B229]). Moreover, self-assembling peptides (SAPs) have been used to generate hydrogel to support human NSC differentiation into neurons, *in vitro*, in 3D, and to test the neuroregenerative potential in rat spinal cord injuries ([@B230]). Further, graphene composites have been optimized to promote human NSC differentiation and to increase conductivity and electroactivity ([@B231], [@B232]), a useful strategy for peripheral nerve recovery ([@B233]).

Lastly, the therapeutic plasticity of NSCs can also be exploited in drug target validation and testing. Indeed, primary cells have the best physiological relevance, but they are limited in availability, expansion, and reproducibility, and for some diseases, they are not accessible at all. In contrast, stem cells can be propagated for a long period of time, can be cryopreserved, and can be differentiated *in vitro* into a particular lineage to model a specific disease. Moreover, research and developmental efforts have been put in place in biotech and pharmaceutical companies to generate cells for high-throughput screening ([@B234], [@B235]). Further, since iPSCs from patients can be differentiated into specific lineages, patient-specific derived cells have been proposed for personalized medicine. The technology is surely going to translate to the clinic for monogenic rare hereditary diseases, where iPSCs provide a model to compensate for the lack of predictive human samples or for *in-vivo* preclinical models, since CRISPR/Cas9 technology or genome manipulation can help to introduce mutations of interest ([@B179], [@B236]).

Moreover, the possibility of assessing the molecular consequences of drug testing at specific stages of differentiation will help to identify active pathways and possible mechanisms for target identification ([@B237]). Bioinformatics, machine-learning algorithms, and big data tools for pattern recognition can be efficiently used for data analysis, orthogonal target validation, and biomarker discovery.

Technological Advances in the Field of NSCs That Leverage Their Therapeutic Plasticity {#s6}
======================================================================================

Recent technological advances in the field of stem cells and molecular biology have helped to potentiate their therapeutic efficacy. For example, gene therapy through the over-expression of key genes that encode for proteins with bystander potential has recently been proposed (gene therapy). This strategy has been applied to exogenous NSCs for important growth factors like NGF and BDNF. Indeed, adult human olfactory bulb neural stem/progenitor cells expressing NGF increased their proliferation and oligodendrocytic differentiation potential ([@B238]), while ESC-derived NPC expressing BDNF presented enhanced neuronal and striatal *in vivo* differentiation and turned out to be useful in Huntington\'s disease ([@B239]). Similarly, transplant of PSA-NCAM neural progenitors expressing BDNF was therapeutically useful in a mouse model of spinal cord injury ([@B240]), while embryonic rat NSCs expressing BDNF stimulated synaptic protein expression and promoted functional recovery in a rat model of traumatic brain injury ([@B241]). Of note, tumor formation was completely absent ([@B242]). Overexpression of GDNF was instead effective in stroke ([@B243]). The strategy has been applied not only to growth factors but also to transcription factors, such as Nurr1 ([@B244]), a critical gene in the embryonic differentiation of dopaminergic neurons ([@B245]).

Similarly, recombinant adeno-associated virus rAAVr3.45-IL10-infected human NSCs (HFT13) have been transplanted to evaluate their potential in ischemic injuries. Overexpressed IL10 had immunomodulatory effects and accelerated the recovery of neurological deficits and the reduction of brain infarction volume ([@B246]).

Engineering strategies using genome editing via CRISPR/Cas9 are being deployed on NSCs to precisely insert a gene of interest in the safe harbor human and mouse *loci* of AAVS1 and Rosa26, to perform a biallelic knockout of neurodevelopmental transcription factor genes, and to knock-in tags and fluorescent reporters ([@B247]). More recently, gene targeting at multiple *loci* using Cas9 showed great promise for a wide range of neurodegenerative disorders and injuries of the CNS, including lysosomal storage disorders ([@B248]). More sophisticated technological advances in the genome-editing field are being developed ([@B249]). Leveraging CRISPR/Cas9 for genes with ascertained therapeutic potential and with a spatio-temporal control might be possible to further harness the therapeutic plasticity of NPCs ([Figure 9](#F9){ref-type="fig"}).

![Engineering strategy to potentiate the therapeutic plasticity of neural stem cells. Transplant of NPCs in suitable preclinical neurodegenerative inflammatory and demyelinating disease models \[stroke, Pelizaeus-Merzbacher disease (PMD), or multiple sclerosis\], cell recovery from the pathological tissue, and then sequencing allow the identification of key molecules that exert the therapeutic effects. Further, NPCs can be engineered to potentiate *ad hoc* the expression of therapeutic targets and rescue the brain-healthy phenotype.](fneur-11-00148-g0009){#F9}

The discovery of induced pluripotency, which forces terminally differentiated adult somatic (i.e., blood or fibroblasts) cells into the pluripotent state, has provided the possibility of modeling complex neurological disorders ([@B250]). Differentiated cells are useful for screening drug candidates that can rescue molecular, cellular, and functional abnormalities in disease-specific hiPSC-derived cell types and offer the possibility of performing personalized medicine ([@B251]). In this same context, reprogramming or direct conversion of somatic cells using a non-viral system (liposome or cationic polymers) represent an interesting alternative in the perspective of clinical applicability (due to the reduced risk of tumor formation). Similarly, several types of nanoparticles useful for reprogramming have been developed. Graphene oxide-polyethylenimine complexes represent an efficient and safe system for mRNA delivery for direct reprogramming of somatic cells to induce neurons ([@B252]). Overall, on one side, the possibility of expanding *in vitro* hiPSC-derived NPCs opens up the perspective of autologous transplant and, on the other, NPCs derived from cells obtained with the new reprogramming strategy might overcome current hurdles associated with NPCs of conventional origin (both primary and from reprogrammed somatic cells) ([@B253], [@B254]).

It is becoming more and more important to be able to image the behavior of adult NSCs *in vivo* to explore how and where activation and division occur ([@B255]). This might be achieved with powerful microscopic and technological advances. With this aim, novel imaging sensors and tools have been developed for MRI technology, which provides excellent image quality, sensitivity, and 3D spatial resolution. Gadolinium (III) (Gd^3+^) is the heavy metal contrast agent conventionally used in clinical and animal experimental MRI. Manganese (Mn^2+^) is another useful positive T1 contrast agent that is widely used ([@B256]), similarly to iron oxide particles (SPIO), which have even higher sensitivity, better biocompatibility (function and phenotype), and increased paramagnetic power ([@B257]). Nonetheless, there are limitations in labeling stem cells with magnetic contrast agents because the label could be diluted due to stem cell proliferation after transplant. Moreover, particle loading allows stem cell tracing, but it is not informative regarding the survival state of stem cells and of possible changes induced in and by the microenvironment. Indeed, the signal could come from dead transplanted cells or cells phagocytized by microglia ([@B258]). MRI has also been improved using super-paramagnetic nanoparticles (MPI) ([@B259]) not present in biological samples, such as fluorine-19 (^19^F), a strategy that is suitable for quantification and is devoid of the ambiguity of contrast tracking ([@B260]). In addition, the resolution has been augmented by increasing the number of coil receiver channels, the strength of the magnetic field, and the number of image acquisitions.

Nuclear medicine imaging techniques, such as positron emission tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), represent other promising imaging modalities for tracking stem cells. SPECT has gamma camera detectors for gamma-ray emissions from the tracers (up to two different radioisotopes at the same time) injected into the patient. PET instead measures the decay effect of different radioisotopes that emit positrons, which interact with electrons from the body, are annihilated, and generate two gamma photons emitted in opposite directions.

^111In^-oxyquinoline, ^99^mTc-HMPAO, and, mainly for the CNS, ^18^F-FDG or 2-deoxy-^18^F-FDG, 3′-deoxy-3^′18^F-FDG have been used for non-invasive imaging of NSC proliferation with PET ([@B261], [@B262]). It is still crucial to identify the safe dose of a radiotracer.

As an alternative to isotope cell loading and to overcome problems associated with particle loading, MRI reporter genes have been introduced for stable and robust tracking of implanted stem cells ([@B263]). The "imaging reporter genes" strategy consists of the production of a particular protein that interacts with a radioactive probe whose signal can be detected by PET/SPECT for a long time without being limited to the half-life of the tracer. With this approach, only living cells will be detected, excluding false signals ([@B264]). Cell labeling has been performed with green fluorescent protein (GFP) and red fluorescent protein (RFP), as well as with some fluorescent dyes, such as DiD, Dil, and indocyanine Green or semiconductor nanocrystals called quantum dots (QD). QDs emitting in the Near-infrared-(NIR) have been already used to track transplanted cells in the human brain ([@B265]).

Moreover, the introduction of a reporter gene that encodes for a special luciferase protein (bioluminescence imaging, BLI) has been widely applied in preclinical studies of stem cell imaging in the brain ([@B266]). Combining the high anatomical spatial resolution of MRI and the high sensitivity of PET with BLI was very useful for sensitivity and precise localization. Multimodality imaging can also be used, combining fluorescent QDs with magnetic nanoparticles ([@B267]).

Single-cell sequencing represents another fundamental technological advancement that enables the temporal and spatial dynamics of stem cells to be exploited. Since NPCs are significantly heterogeneous, each line maintained *in vitro* would need to be deeply characterized to assess the level of heterogeneity. Further, single-cell sequencing *ex vivo* on recovered transplanted cells will help develop an understanding of the therapeutic profile exploited in specific pathological conditions ([Figure 9](#F9){ref-type="fig"}).

Obtaining data at the single-cell level helps with understanding how different types of brain cells develop and with identifying key genes to be used for cell engineering. Studies in drosophila represent an excellent model system with which to investigate how spatial and temporal factors are integrated during neurogenesis and can be translated to deep characterization in mammals ([@B268]).

Pros and Cons of Harnessing Therapeutic Plasticity {#s7}
==================================================

Harnessing neural plasticity is important due to its potential to support brain healing and rewiring to fight neurological and neurodegenerative diseases and, given the physical-chemical interaction between the SVZ and the striatum, to tune neuropsychological behavior that is often associated with neurodegenerative disorders. Indeed, the neural niche represents a reservoir of cues that influence proper brain cognitive functions and decisions. An altered concentration of released soluble factors by the stem niche may be responsible for unhealthy maintenance of striatal interneurons and for modified behavioral adaptation and striatum functions, ultimately leading, in extreme conditions, to obsessive--compulsive disorders. Of note, alterations in adult neurogenesis have been linked to psychiatric disease in humans ([@B269], [@B270]). According to the neurogenic hypothesis, major depressive disorder (MDD) is linked to impairments of adult neurogenesis in the hippocampal DG, and antidepressants are efficacious because they increase neurogenesis ([@B271]).

Harnessing therapeutic plasticity is tantalizing, not only to balance neuronal or neurodegenerative disorders but also to open up new learning opportunities in adulthood when conventional pruning, mediated by the environmental inputs in the early phase of brain development, has already occurred and connections have already been established, through a "use it or lose it" principle. Further, this approach can be translated to aging conditions and might be useful for preserving neuronal integrity.

Plasticity is important, but the brain also needs stability. Pharmacological or genetic modification can indeed increase plasticity, but a targeted and balanced (in time and amount) intervention is fundamental because excessive release of trophic factors might be detrimental. For example, brain overexposure to TGFβ2 as an anti-inflammatory approach ([@B272]) might cause a malignant TGFβ2 autocrine loop that leads to glioblastoma ([@B273]). Excessive plasticity could also be detrimental because massive memory capabilities \[Savant abilities ([@B274])\], a reflection of over-plasticity, are linked to autistic profiles, because plasticity degenerates in chaos ([@B275]). For those reasons, engineered molecular tools should be responsive to and controlled by environmental signals.

Adult NSCs reside in restricted areas of the adult CNS and have limited capacity to proliferate ([@B276]). Thus, *in vitro* expansion is a limiting factor, and growth in suspension can be troublesome. Therefore, culture in adhesion has been developed using different coatings with the ultimate goal of maintaining stable expression of stem markers, such as Nestin and Sox2. Moreover, it is always important to consider that neurospheres may be heterogeneous because they are not derived from a single NSC. On the other hand, a limited proliferation capacity might be advantageous for ensuring that NSCs do not present tumorigenic potential, and genetic stability from one passage to another is likely to be maintained.

From the perspective of expanding neural precursors in culture at large scale, the iPSC technology has helped with the generation *in vitro* of expandable and freezable samples. However, although iPSCs are an important source of NPCs, caution is necessary because of the potential risks at the genomic and epigenomic level ([@B277]). Further, NSCs derived from iPSCs could cause rejection, so they might need to be combined with an immunosuppressant. The development of non-immunogenic iPSC-based therapies is very important to minimize the probabilities of patient rejection. Nonetheless, NSCs remain the best solution for neurological diseases, compared with other stem cell types, since recovery can be promoted not only by indirect paracrine effects but also by direct neural cell replacement, which is not supported by other sources of stem cells of another developmental origin, making the latter unable to properly differentiate in the CNS ([Figure 10](#F10){ref-type="fig"}).

![NSC plasticity as a function of origin (x-axis) and therapeutic use (y-axis). NSCs originate both from physiological niches and from *in vitro* manipulation. Their therapeutic potential is exploited with different strategies, as depicted in the lower part of the illustration.](fneur-11-00148-g0010){#F10}

Conclusions {#s8}
===========

The discovery of neural stem cells and their potential has revived the field in terms of functional cell replacement, and concerns related to the risk of tumor formation have been dampened because the majority of NSC transplantation studies revealed no tumor formation. NSCs are a promising therapeutic approach for neurodegenerative disease. They can differentiate and replace the lost neural tissue as well as secreting neurotrophic factors that can protect or regenerate. Nonetheless, further studies are needed to quantify doses and administration periods and to define the most promising cellular NSC source considering also combined therapies to take NSCs/NPCs close to pharmacological prescription.
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